Navigation Links
London Genetics and Astrimmune to Collaborate on Cancer Vaccine
Date:11/12/2010

London Genetics and Astrimmune to Collaborate on Cancer Vaccine -- LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Joint Ventures, New Products & Services Click to view news release full screen  

London Genetics and Astrimmune to Collaborate on Cancer Vaccine

 

LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme. The plan, for Astrimmune's early-stage pancreatic cancer vaccine candidate, will be used in applications for further funding of its development. Financial terms were not disclosed.

Astrimmune's vaccine candidate induces the production of antibodies against gastrin, a hormone which is known to stimulate the growth of many types of gastrointestinal cancer. Since differential response rates have been observed in clinical trials of other gastrin-blocking products, with some patients responding very well and others hardly at all, there is a clear need for biomarkers to help identify those patients most likely to benefit from Astrimmune's product. For example, there is a possibility that the variable response rates may have been due in part to the inclusion of some patients with gastrin-insensitive tumours, or those not able to respond immunologically.

Under the terms of the collaboration, which is supported by a grant from the UK East Midlands Development Agency, London Genetics and Astrimmune will put together a proposal for identification of biomarkers predictive of clinical response. London Genetics' seven academic partners, which have an annual research budget of over GBP650m, are able to provide expertise in areas such as tumour biopsy samples and animal models, as well as expertise in the genetics of immune responses to cancer vaccines.

Dominique Kleyn, CEO of London Genetics, said, 'This collaboration is a significant pharmacogenetics development opportunity, and we are pleased to be working with Astrimmune on this important project. As exemplified by our recent collaboration with Diaceutics and increasingly recognised by the biopharmaceutical industry, pharmacogenetics, biomarkers and patient stratification are becoming an important part of the drug discovery and development process. London Genetics' network of over 3,000 academic groups makes it an ideal partner for pharma and biotech companies in this work.'

Fred Jacobs, Managing Director of Astrimmune, said, 'Pancreatic cancer is an area of serious unmet medical need, with a five-year survival rate of around 5% and few treatment options. Availability of a biomarker to select those patients mostly likely to benefit from Astrimmune's vaccine candidate can be expected to expedite the development of this product and increase its chances of coming to market in the future. London Genetics is an expert in this area and Astrimmune is delighted to be working with the company on this important part of the project development.'

About London Genetics: London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise, based on its access to 3,000 academic groups with a GBP650m annual research spend. Recent deals by London Genetics include a partnership with Diaceutics to accelerate biomarker development in the biopharmaceutical industry. LGL is based in central London and has ISO 9001 accreditation. For further information, please go to http://www.londongenetics.com

About Astrimmune: Astrimmune (Company Registration: 06379008), is a limited, social enterprise company developing treatments for gastrointestinal cancers. Astrimmune is focussed on the elimination of cancer growth factors that are not yet commercialised and is progressing a new immunogen vaccine candidate for use in gastro-intestinal cancers. The distillation of their prior knowledge, coupled with a research programme to refine patient selection to identify the most responsive patients, provides for an accelerated, low cost development path with an increased chance of successful product registration in the EU and the US. For further information, please go to http://astrimmune.blogspot.com/

For further information please contact: London Genetics Ltd Dominique Kleyn, CEO +44(0)207-594-1838 Emma Palmer Foster, Strategic Communications Consultant +44(0)7880-787185 communications@londongenetics.com Astrimmune Fred Jacobs, Managing Director +44(0)7989-386326
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
2. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. First Awards Made by London Genetics Proof-of-Concept Fund
5. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
6. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
7. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
8. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
9. Interleukin Genetics Reports Third Quarter 2010 Financial Results
10. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
11. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The book, ... for IT services, what questions to ask your IT consultant before signing a contract ... to your computer network. , “With companies relying heavily on e-mail and technology, it’s ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):